Scoville B, Mueller B, White B G, Krieglstein G K
Office of Clinical Research, Otsuka Pharmaceutical Co., Rockville, Maryland 20850.
Am J Ophthalmol. 1988 Feb 15;105(2):150-4. doi: 10.1016/0002-9394(88)90178-x.
We performed a double-masked study in which 98 patients with ocular hypertension who had been previously treated with timolol received either timolol 0.25% or carteolol 1%, a beta-blocker with intrinsic sympathomimetic activity. The drugs were administered topically twice daily for one month after a one-week washout period. Intraocular pressure was measured at baseline and after one and four weeks of treatment. The appearance of the fundus, external eye, visual fields, tear secretion, blood pressure, and pulse were recorded. Adverse symptoms were elicited using a menu-type questionnaire and an overall judgment of therapy was recorded. Carteolol was as effective as timolol in reducing intraocular pressure. There were significantly fewer patients reporting adverse events overall (P = .019), and eye irritation specifically (P = .02), in the group treated with carteolol.
我们进行了一项双盲研究,98例曾用噻吗洛尔治疗的高眼压患者,分别接受0.25%噻吗洛尔或1%卡替洛尔(一种具有内在拟交感活性的β受体阻滞剂)治疗。在为期一周的洗脱期后,药物每日局部给药两次,持续一个月。在基线以及治疗1周和4周后测量眼压。记录眼底、眼外部、视野、泪液分泌、血压和脉搏的情况。使用菜单式问卷引出不良症状,并记录对治疗的总体判断。卡替洛尔在降低眼压方面与噻吗洛尔同样有效。总体而言,卡替洛尔治疗组报告不良事件的患者明显较少(P = 0.019),特别是眼部刺激症状(P = 0.02)。